L’Oréal settles first four claims in hair relaxer cancer trial
Four women alleging that chemical hair relaxers contributed to their gynecologic cancers reached a confidential settlement with L’Oréal USA and other manufacturers during the first trial in thousands of related lawsuits. The settlement does not establish liability, and L’Oréal says it stands by the safety of its products and that the research does not prove they caused the women’s illnesses. More than 12,700 cases are consolidated in federal court in Chicago, with additional claims pending in state courts. The lawsuits followed a 2022 National Institutes of Health study that found frequent use of hair straighteners was associated with more than twice the risk of uterine cancer; the products have been widely marketed to Black women.




